| Dr Manthan Dipak Makadia, MD | |
|
1721 Ebenezer Rd Ste 175, Rock Hill, SC 29732-1188 | |
| (804) 324-5256 | |
| Not Available |
| Full Name | Dr Manthan Dipak Makadia |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 13 Years |
| Location | 1721 Ebenezer Rd Ste 175, Rock Hill, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396005773 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MT201295 (Pennsylvania) | Secondary |
| 208600000X | Surgery | 2021-01921 (North Carolina) | Secondary |
| 208600000X | Surgery | 86393 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Medical Center | Rock hill, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Surgical Specialists Of Charlotte Pa | 3779519285 | 33 |
| Surgical Specialists Of Charlotte Pa | 3779519285 | 33 |
News Archive
A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of new COVID-19 variants.
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.
› Verified 5 days ago
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437607686 PECOS PAC ID: 3375449655 Enrollment ID: O20040115000819 |
News Archive
A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of new COVID-19 variants.
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.
› Verified 5 days ago
| Entity Name | Surgical Specialists Of Charlotte Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073599734 PECOS PAC ID: 3779519285 Enrollment ID: O20050714001059 |
News Archive
A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of new COVID-19 variants.
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.
› Verified 5 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of new COVID-19 variants.
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.
› Verified 5 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of new COVID-19 variants.
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Manthan Dipak Makadia, MD Po Box 33369, Charlotte, NC 28233-3369 Ph: (704) 916-2108 | Dr Manthan Dipak Makadia, MD 1721 Ebenezer Rd Ste 175, Rock Hill, SC 29732-1188 Ph: (804) 324-5256 |
News Archive
A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of new COVID-19 variants.
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active.
Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.
› Verified 5 days ago
Dr. Kamran Borhanian, MD Surgery Medicare: Medicare Enrolled Practice Location: 200 S. Herlong Ave., Suite G, Rock Hill, SC 29732 Phone: 803-909-6300 Fax: 803-909-6310 | |
Dr. Shamly Venus Dhiman, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1721 Ebenezer Rd, Suite 175, Rock Hill, SC 29732 Phone: 803-324-5256 Fax: 803-328-0440 | |
Dr. Christopher W Schroeder, MD Surgery Medicare: Medicare Enrolled Practice Location: 1721-07 Ebenezer Road, Suite 175, Rock Hill, SC 29732 Phone: 803-324-5256 Fax: 803-328-0440 | |
Dr. Robert D Randall Jr., MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1665 Herlong Ct, Suite A, Rock Hill, SC 29732 Phone: 803-329-8500 Fax: 803-329-8511 | |
Corey K Crain, MD Surgery Medicare: Medicare Enrolled Practice Location: 1721 Ebenezer Rd Ste 175, Rock Hill, SC 29732 Phone: 803-324-5256 Fax: 803-328-0440 | |
Carrie Dawn Watson, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Herlong Ave S Ste G, Rock Hill, SC 29732 Phone: 803-909-6300 Fax: 803-909-6310 |